Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

CRDF

$1.21+15.24%

Cardiff Oncology, Inc.

Market Cap
$82M
Sector
Materials
Industry
Biotechnology
Beta
1.45
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
26.4x
buying
Congress
—
recent trades
Short Volume
52%
W/W +2.0pp

Market & Alt Data

News
11
recent articles
Activist
13D
ACORN
Analyst Consensus
Buy
12 analysts
Velocity Score
26.39x
Current Rate (90d)
8626.13/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
4
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-07-142026-07-16PACE GARY WDirectorPurchase687.3K$1.46$1000K2.04MView
2026-07-142026-07-16Mohindru ManiDirector & Chief Executive OfficerPurchase34.4K$1.46$50K59.1KView
2026-06-182026-06-22Mohindru ManiDirector & Chief Executive OfficerPurchase24.7K$1.21$30K24.7KView
2026-06-182026-06-22PACE GARY WDirectorPurchase30.0K$1.22$37K1.36MView
2025-07-302025-07-31PACE GARY WDirectorPurchase290.0K$2.45$711K1.35MView

Recent News

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow
SeekingAlpha · 2026-09-10
Stay updated with the stocks that are on the move in today's after-hours session.
ChartMill · 2026-09-09
Cardiff Oncology to Participate in September 2026 Conferences
Yahoo · 2026-09-02
CRDF: Second Quarter Earnings
Yahoo · 2026-08-17

Informational purposes only, not investment advice.

William Blair Downgrades Cardiff Oncology to Market Perform
Benzinga · 2026-08-12
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Yahoo Finance · 2026-08-11
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
Yahoo Finance · 2026-07-15
Cardiff Oncology Announces $10 Million Registered Direct Offering
Yahoo Finance · 2026-07-15
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
Yahoo Finance · 2026-06-30
CRDF: Phase II Update; Survival Advantage Extended
Yahoo Finance · 2026-06-22
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Yahoo Finance · 2026-06-02

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →